Christoph Esslinger
Fondateur chez Memo Therapeutics AG
Profil
Christoph Esslinger was the founder of CT Atlantic Ltd.
(founded in 2008) where he held the title of Chief Technology Officer and Memo Therapeutics AG (founded in 2012) where he held the title of Director & Chief Scientific Officer.
He also worked as a Director-Antibody Technologies at Neurimmune Therapeutics.
Dr. Esslinger received a graduate degree from Universität Stuttgart and a doctorate degree from the University of Lausanne.
Postes actifs de Christoph Esslinger
| Sociétés | Poste | Début |
|---|---|---|
Memo Therapeutics AG
 Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Fondateur | 29/11/2012 |
Anciens postes connus de Christoph Esslinger
| Sociétés | Poste | Fin |
|---|---|---|
| Neurimmune Therapeutics | Corporate Officer/Principal | - |
CT Atlantic Ltd.
 CT Atlantic Ltd. Miscellaneous Commercial ServicesCommercial Services CT Atlantic AG focuses on the identification and development of human-derived monoclonal antibodies as novel therapeutics for the treatment of cancer. The company was founded by Alexander Knuth, Christoph Esslinger and Edward Stuart in 2008 and is headquartered in Schlieren, Switzerland. | Fondateur | - |
Formation de Christoph Esslinger
| Universität Stuttgart | Graduate Degree |
| University of Lausanne | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
CT Atlantic Ltd.
CT Atlantic Ltd. Miscellaneous Commercial ServicesCommercial Services CT Atlantic AG focuses on the identification and development of human-derived monoclonal antibodies as novel therapeutics for the treatment of cancer. The company was founded by Alexander Knuth, Christoph Esslinger and Edward Stuart in 2008 and is headquartered in Schlieren, Switzerland. | Commercial Services |
| Neurimmune Therapeutics | |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Health Technology |